Serum Androgen Levels as a Marker for the Severity of Preeclampsia
1 other identifier
observational
75
1 country
2
Brief Summary
this study will be conducted to confirm the hypothesis of the previous studies and to list the high androgen levels as a precipitating factor for preeclampsia
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2017
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2018
CompletedFirst Submitted
Initial submission to the registry
November 15, 2018
CompletedFirst Posted
Study publicly available on registry
November 19, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
April 30, 2019
CompletedNovember 20, 2018
November 1, 2018
9 months
November 15, 2018
November 17, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
serum androgen levels as a marker for the severity of preeclampsia
assess if serum androgen levels could be used as a marker for the severity of preclampsia
1 week
Study Arms (3)
control group
serum androgen levels will be measured in 25 normotensive pregnant women
mild preeclampsia
serum androgen levels will be measured in 25 mild preeclamptic patients
severe preeclampsia
serum androgen levels will be measured in 25 severe preeclamptic patients
Interventions
measurement of serum free and total testosterone
Eligibility Criteria
patients will be divided into 3 groups 1. control group : 25 normotensive pregnant women 2. mild preeclampsia: 25 mild preeclamptic patients 3. severe preeclampsia : 25 severe preeclamptic patients
You may qualify if:
- Pregnant women (primigravidas).
- Age between 20 and 35 years old.
- Live fetus.
You may not qualify if:
- Women younger than 20 years old and older than 35 years old
- Intrauterine fetal death.
- History of pre-gestational hypertension.
- History of hormonal disorders (thyroid gland disorders and hyperprolactinemia).
- Smoker.
- Polycystic ovary syndrome.
- Signs or symptoms of hyper-androgenism (hirsutism, acne, oily skin, etc.).
- Diabetes mellitus.
- Drug use except ordinary supplementation (iron, folic acid).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Ain Shams University
Cairo, Egypt
AinShams University
Cairo, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Joseph A Ibrahiem, student
Ain Shams University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 1 Week
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
November 15, 2018
First Posted
November 19, 2018
Study Start
October 1, 2017
Primary Completion
June 30, 2018
Study Completion
April 30, 2019
Last Updated
November 20, 2018
Record last verified: 2018-11